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In this issue of the Journal . Natale et al . (1) report clinical
advantages of a hybrid biphasic nonthoracotomy defibrillat-
ing system compared with their earlier experience using a
monophasic device with a congruently designed transvenous
defibrillating lead system. This involved preliminary clinical
results in patients receiving a standard CPI monophasic
implantable cardioverter-defibrillator versus a biphasic im-
plantable cardioverter-defibrillator (Cadence, Ventritex) us-
ing the same CPI Endotak (C-60) transvenous lead system
with both devices . The authors report lower defibrillation
thresholds and improved clinical efficacy and utility (de-
creased implantation time, shorter patient recovery time and
higher implantation rate) based on a retrospective compari-
son of a new hybrid defibrillating system with an earlier
clinical investigational experience .
The art of medicine reflects individual innovation . The
science of medicine reflects identifiable variables and mea-
surable outcomes . Clinical efficacy and safety (clinical util-
ity) encompasses both science and art from the diverse
perspectives of the public, the regulatory agencies re-, ,, -nsi-
ble for public safety, competing manufacturers and the
medical community, It is the physician's role to responsibly
advance the art and science of medicine for patient benefit .
Natale et al, recognized some of the uncertainties surround-
ing the use of hybrid defibrillating systems, but they may be
creating more controversy instead of advancing the art and
science of medicine .
t study. Natale et al. (1) failed to address the
starting and termination dates of both series, the investiga-
tional protocol status of the nonhybrid implantable cardio-
verter-defibrillator system, differences in implantation pro-
tocol, the "learning curve" influence and available
alternative therapies while advancing the advantages of
biphasic hybrid use . The report lacks data and description
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with regard to sensing . It only addresses the value of
biphasic versus monophasic defibrillation . There are no
comments about inappropriate shocks, nor in fact is there a
specific comment with regard to observed or potential sens-
ing problems with the Endotak (C-60) lead with its design-
matched device or in a "mix and match" configuration . The
primary safety issue with an Endotak (C-60) lead in a "mix
and match" configuration is sensing (2,3) . The authors
provide no observations in their report with respect to the
safety and efficacy of sensing ; however, they infer that the
hybrid biphasic system is safer and more clinically effica-
cious. Only through careful inspection of the report does it
become apparent that the observations are limited to im-
provement in biphasic compared with monophasic defibril-
lation thresholds (p = 0.03). Proper antitachycardia system
function is dependent on both accurate tachycardia recogni-
tion and effective termination response . The rate-sense
signal from the Endotak integrated bipole has characteristics
different from the standard dedicated bipole . If the Endotak
lead, with its integrated bipole rate signal, is combined with
other manufacturers' devices, their sensing schemes might
lead to detection abnormalities and misdirected therapy .
Implications and problems . When addressing the issue of
"mixing and matching" devices for arrhythmia management
that have not been formally tested in such a combination,
one should assume that a patient who is refractory to
approved therapy and has no other alternatives is likely to
benefit according to the expertise of the physician ("taking
the high road"). One could also take the "low road" and
assume that for marketing purposes and "leap-frogging
technology around the Food and Drug Administration
(FDA)," clinicians, in concert with manufacturers, are try-
ing to advance certain technology independent of the st iftc
needs of an individual patient . The specific patient may
benefit, or the patient may not experience beneficial or
adverse results, or the patient may be harmed. Unfortu-
nately, this type of clinical experience (clinical data) cur-
rently does not contribute to the regulatory dex; V : :
Furthermore, even data from sound clinical investigations
do not influence the regulatory device evaluation process .
This frustrates physicians and encourages them to circum-
vent the FDA . Also, reports such as that of Natale et al .
enable biased parties to inform, misinform or disinform the
medical community with regard to the efficacy and safety of
a mixed and matched system .
The physician should follow the guidelines for safety and
efficacy for a specific patient unless or until the patient's
particular and peculiar clinical presentation necessitates
innovation. Then it is up to the physician to improvise in a
manner that is most likely to benefit the patient and least
likely to cause harm . The obligation of the physician is to
gain knowledge, to educate colleagues and always to provide
continuously improved patient care. If Natale et al . are
directly or indirectly supporting the hybrid use of this
particular combination as a standard or an acceptable norm,
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they therefore should clearly address the efficacy and safety
issues of defibrillation as well as the efficacy and safety
issues of sensing because both aspects are equally important
for effective defibrillation therapy . The specific issues of
sensing were well known at the time of the preparation of
this report . Certainly, it is the prerogative of the authors to
take their limited approach ; however, they then should state
to the reader that there are other issues involved and that
they can be found by consulting various references .
The dilemmas of pursuing continuous improvement in
clinical practice, The FDA has encouraged industry to do
the following: 1) avoid device marketing for out of label use ;
2) police and discourage the use of out of label devices by the
medical community ; 3) apply for investigational device ex-
emption to formally test mixing and matching of implantable
cardioverter-defibrillator systems . The FDA is also encour-
aging physicians and researchers, in cooperation with man-
ufacturers, to apply for individual investigational device
exemptions to test innovative technologies in a manner that
facilitates subsequent FDA data analysis. Unfortunately, the
process of obtaining this type of investigational device
exemption is cumbersome. Fortunately, the FDA is commit-
ted to streamlining this process in the near future . The use of
mixing and matching should depend on relative risk . Mixing
and matching in pacing is more readily tolerated because of
less critical electromechanical interfaces and much less
critical clinical sequelae . Mixing and matching of implant-
able cardioverter-defibrillator systems is potentially more
dangerous . The CPI device and the CPI Endotak lead were
"tuned" to function as a system. The use of one company's
device with another company's lead system presents greater
risk and more potential difficulty . This type of mixing and
matching also provides the potential for achieving the best
system . The only way to tell is to acquire sound scientific
data .
Physicians should have the right to mix and match when
it is to the patient's benefit and when alternative, approved
systems are not available. One steps into an uncertain,
vulnerable position when mixing and matching without clear
clinical indication for the specific patient . The risks of mixing
and matching exist and may prove not to be significant ;
however, they are currently unknown . Physicians should
follow the rules of what is safe and effective until the patient
becomes refractory to established therapies ; then it is up to
the physician to improvise for the best therapy according to
his or herjudgment. The only solution is continuous dialogue
MALONEY ET AL.
	
415
EDITORIAL COMMENT
between the medical provider, the manufacturer and the
regulatory body to achieve the cow -non mission of improved
patient care that includes access to new technology
. It is
unfortunate that Nwaleet al . and others are forced to pursue
this mix and match approach of third-generation LCD tech-
nology, whereas our colleagues in Europe are now success-
fully applying fourth- and fifth-generation ICI technology
that was designed in the United States but transported
overseas because of regulatory barriers. Concurrent with
these regulatory barriers are the recent attempts by Medi-
care and the Office of the Inspector General to limit use of
certain medical procedures and devices that physicians
believe have been shown to be safe, effective and superior to
other therapies but are not yet FDA approved (New York
Times, Saturday, June 18, 1994) . Les Aspin, our former
Secretary of Defense, received a pacemaker outside of
labeled indication, yet the same type of application would
now not be reimbursed by Medicare . Further government
controls and cost savings may well limit access for the poor
and elderly to the latest and best medical options . In
addition, these controls will likely stifle U .S. advances in
clinical research that have set our medical system apart from
others worldwide . This type of two-class medical delivery
system is the rule rather than the exception worldwide,
where long lines and inferior medical care are the norm for
all but those who can afford access to a private system . We
must avoid a system that provides first-rate modern therapy
for only those who can afford the best U .S. technology
applied in foreign lands but limits access to the best medical
care for the less fortunate, including the elderly and the
poor. A reformed national health care system that functions
under government rules similar to Medicare will certainly
ration the best technology and medical care for everyone
when cost is the primary issue .
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